IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
2024年4月5日 - 9:30PM
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical
company developing novel, immune-modulating therapeutic cancer
vaccines based on its T-win® platform, today announced that Faiçal
Miyara, Ph.D., has been appointed as the company’s chief business
officer. Dr. Miyara, who has more than 17 years of experience in
the pharmaceutical industry, will be responsible for global
business development activities including strategic partnerships.
Dr. Miyara will be based in the United States, report to IO
Biotech’s CEO, Mai-Britt Zocca, Ph.D., and be a member of the
company’s executive team, effective immediately.
“We are very excited to welcome Faiçal to IO
Biotech,” said Dr. Zocca. “His deep experience in business
development with proven ability to execute strategic transactions
will be invaluable as we look at opportunities to advance our
wholly owned proprietary T-Win platform. The coming months will be
a critical period for the development of our company with the
outcome of the pivotal Phase 3 interim analysis of our lead
therapeutic cancer vaccine, IO102-IO103, expected in the third
quarter of this year, as well as the readout of the primary
endpoint of progression free survival estimated to follow in the
second half of 2025.”
Dr. Miyara added, “I am thrilled to join the IO
Biotech team at this important time in the company’s development. I
believe the novel dual-mechanism approach of the vaccines being
developed is very promising and has the potential to significantly
improve the current treatment paradigm for people living with
cancer. I look forward to developing new partnerships to further
progress the company’s growing portfolio.”
Dr. Miyara is a seasoned executive with nearly
two decades of experience in the pharmaceutical and biotechnology
industry with a track record of successful deals and partnerships
across several key therapeutic areas. Most recently, he served as
Vice President, Head of Business Development Oncology, then Head of
External Innovation Oncology, Lead on Venture Capital Activities at
Ipsen Biosciences. Prior to this role, he was Senior Vice
President, Head of Business Development and External Research at
Kadmon Corporation. Earlier in his career, Dr. Miyara served in
leadership roles at Pfizer and Eli Lilly and Company. Dr. Miyara
holds a Ph.D. in reproductive, molecular, and cellular biology from
the Université Pierre & Marie Curie Paris, and a Master of
Engineering of Medical Biology degree from Université Joseph
Fourier Grenoble.
Inducement Equity Awards
In connection with Dr. Miyara’s acceptance of
employment with the company, Dr. Miyara will, as of the close of
business on April 5, 2024, be granted a non-statutory option to
purchase 310,000 shares of the company’s common stock. The option
will vest over four years, with 25 percent of the shares vesting on
the first anniversary of Dr. Miyara’s hire date and the remainder
vesting in equal monthly installments over the following three
years. The option will have an exercise price per share equal to
the closing price of the company’s common stock on the grant date,
have a ten-year term, be granted outside of outside of the
company’s 2021 Equity and Incentive Plan, but be governed by the
company’s 2023 Inducement Award Plan, and be subject to the terms
and conditions of stock option agreement covering the grant. The
stock option was granted as an inducement material to the employee
entering into employment with the company in accordance with Nasdaq
Listing Rule 5635(c)(4).
About IO102-IO103
IO102-IO103 is an investigational off-the-shelf
therapeutic cancer vaccine designed to kill both tumor cells and
immune-suppressive cells in the tumor microenvironment (TME) by
stimulating activation and expansion of T cells against indoleamine
2,3-dioxygenase (IDO) and/or programmed death-ligand 1 (PD-L1)
cells. The company is currently conducting a pivotal Phase 3 trial
(IOB-013/KN-D18; NCT05155254) investigating IO102-IO103 in
combination with pembrolizumab versus pembrolizumab alone in
patients with advanced melanoma, a Phase 2 basket trial
(IOB-022/KN-D38; NCT05077709) investigating IO102-IO103 in
combination with pembrolizumab as first line treatment in patients
with solid tumors, and a Phase 2 basket trial (IOB-032/PN-E40;
NCT05280314) investigating IO102-IO103 in combination with
pembrolizumab as neo-adjuvant/adjuvant treatment of patients with
solid tumors.
The clinical trials are sponsored by IO Biotech
and conducted in collaboration with Merck, and Merck is supplying
pembrolizumab. IO Biotech maintains global commercial rights to
IO102-IO103.
KEYTRUDA® is a registered trademark of Merck
Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.,
Rahway, NJ, USA.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical
company developing novel, immune-modulating therapeutic cancer
vaccines based on its T-win® platform. The T-win platform is based
on a novel approach to cancer vaccines designed to activate T cells
to target the immunosuppressive cells in the tumor
microenvironment. IO Biotech is advancing its lead cancer vaccine
candidate, IO102-IO103, in clinical trials, and additional pipeline
candidates through preclinical development. Based on positive Phase
1/2 first line metastatic melanoma data, IO102-IO103, in
combination with pembrolizumab, has been granted a breakthrough
therapy designation for the treatment of advanced melanoma by the
US Food and Drug Administration. IO Biotech is headquartered in
Copenhagen, Denmark and has US headquarters in New York, New
York.
For further information, please visit
www.iobiotech.com. Follow us on our social media channels on
LinkedIn and X (@IOBiotech).
Forward-Looking Statement
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements, including
regarding the timing of the interim and primary analyses of the
company’s Phase 3 trial, current or future clinical trials, their
progress, enrollment or results, or the company’s financial
position or cash runway, are based on IO Biotech’s current
assumptions and expectations of future events and trends, which
affect or may affect its business, strategy, operations or
financial performance, and actual results and other events may
differ materially from those expressed or implied in such
statements due to numerous risks and uncertainties. Forward-looking
statements are inherently subject to risks and uncertainties, some
of which cannot be predicted or quantified. Because forward-looking
statements are inherently subject to risks and uncertainties, you
should not rely on these forward-looking statements as predictions
of future events. These forward-looking statements speak only as of
the date hereof and should not be unduly relied upon. Except to the
extent required by law, IO Biotech undertakes no obligation to
update these statements, whether as a result of any new
information, future developments or otherwise.
Contact:Maryann Cimino, Director of Investor
Relations IO Biotech, Inc.617-710-7305mci@iobiotech.com
IO Biotech (NASDAQ:IOBT)
過去 株価チャート
から 11 2024 まで 12 2024
IO Biotech (NASDAQ:IOBT)
過去 株価チャート
から 12 2023 まで 12 2024